Abstract 370P
Background
LYMPHA is a relatively new surgical technique that dramatically reduces the incidence of lymphedema following axillary node clearance in breast cancer patients. The technique identifies dominant lymph vessels draining the arm with the aid of dye and, following clearance of the axillary nodes, anastomosing lymphatic vessels to a branch of the axillary vein to enable free drainage of lymphatic fluid. Not currently widely available to breast cancer patients in the UK, this simple surgical procedure carried out at the time of axillary node clearance has been shown to reduce the incidence of lymphedema from 25% to 4%. We report on the establishment of a LYMPHA service at a major London Plastics Centre and first 2 years of its outcomes.
Methods
Suitable patients were referred to plastics by the breast surgery team and seen preoperatively to discuss LYMPHA. Upon agreeing to the procedure, pre-operative measurements of arm volume and arm bioimpedance were completed as well as screening questionnaires on symptoms of lymphedema. Subsequent to the procedure the two measurements and the questionnaires were repeated at 1, 3, 6, 12 and 24 month intervals.
Results
Of 16 patients that have undergone the LYMPHA procedure 0 have experienced signs or symptoms of lymphedema to date. One patient suffered temporary swelling of the arm 1-month post-op which subsequently resolved. No patients have suffered any complications relating to LYMPHA. 1 patient withdrew due to metastatic disease recurrence. The patients enrolled have been followed up for between 3-23 months with a current mean follow up time of 12.61 months.
Conclusions
Our findings thus far support current evidence that LYMPHA surgery is both safe and effective in reducing the incidence of lymphedema. This pilot study is currently being developed into an RCT which will add to the evidence base of this relatively niche area of plastic surgery.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
424P - Pyrotinib plus capecitabine for trastuzumab-resistant, HER2-positive advanced breast cancer: Updated survival results from the phase II PICTURE trial
Presenter: Xichun Hu
Session: Poster session 03
425P - Real world quality of life (QoL) in breast cancer (BC) patients treated with cyclin-dependent kinase 4/6 inhibitors (CDK4/6i)
Presenter: Blanca Tavara
Session: Poster session 03
427P - Pyrotinib plus trastuzumab versus pertuzumab plus trastuzumab in patients with HER2-positive metastatic breast cancer: A multicenter, retrospective study
Presenter: biyun Wang
Session: Poster session 03
428P - Palbociclib dose patterns in Swedish patients with metastatic breast cancer: 5-year update from the SIRI study
Presenter: Antonis Valachis
Session: Poster session 03
429P - The impact of HER2 status on the efficacy of CDK 4/6 inhibitors: A multicenter study
Presenter: Hasan Yildirim
Session: Poster session 03
430P - Real-world patient characteristics and treatment patterns in HR+/HER2+ metastatic breast cancer patients in 5 European countries
Presenter: Carmen Criscitiello
Session: Poster session 03
431P - Distribution and prognostic role of HER2 status of circulating tumor cells (CTCs) and tumor-derived extracellular vesicles (tdEVs) in HER2- metastatic breast cancer (MBC) patients (pts)
Presenter: Eleonora Nicolo
Session: Poster session 03
432P - Ki67 and progesterone receptor status could be predict sensitivity to cyclin-dependent kinase inhibitor
Presenter: Lucia Navarro Berlanga
Session: Poster session 03
433P - Effectiveness and safety of vinorelbine + inetetamab + pyrotinib in ≥second-line treatment of HER2-positive metastatic breast cancer
Presenter: Wu Fan
Session: Poster session 03